The New York Times logo

The New York Times Journo Requests

Connect directly with The New York Times journalists and editors. From breaking news to feature stories, discover journo opportunities from this trusted publication.

Latest The New York Times Journo Requests

Founders & Employees at AI Startups - Post-IPO Philanthropy Plans

Everyone's watching the SpaceX/Anthropic/OpenAI IPOs and the wealth they're about to create. NYT DealBook covered it a few days ago; there's real speculation over just how much of this could flow into philanthropy. Timely for me. I'm working on a piece right now about founders and what to do with exit money around philanthropy when a liquidity event hits. Here's what I think matters most for nonprofits right now: Look at who's already in your network, on your board, or in your donor base with ties to these companies. Relationships build over time, not in the weeks after a liquidity event. A few things worth thinking through: → We're going to see a rise in Donor-Advised Funds (DAFs) as an entry point. I'd expect that. → This is a pivotal moment, and not just because of the size of the money. Anthropic and OpenAI are AI companies, and the same technology creating this wealth is going to reshape how philanthropy itself operates: how gifts get sourced, how due diligence gets done, how organizations identify and steward donors. Watching how these founders and employees choose to give may be an early signal of how AI transforms the sector, not just funds it. → Many of these donors will also be earlier in their careers than the ones most gift officers are trained for. That changes the playbook in terms of how we look at generational wealth. The nonprofits and consultants who treat this as a chance to cultivate real, long-standing relationships, not a mailing list update, are the ones who'll still be in the room when the money actually moves. Who's building for this right now? Article linked in the comments

nytimes.com logonytimes.com

People With Lung Cancer In Clinical Trials - Prediction Markets

New York Times seeking perspectives on prediction markets/clinical trials Hi, all, My name is Rebecca Robbins, and I'm a reporter with the New York Times. I write about prescription medicines for the newspaper. You can read my bio and see my recent stories here:https://www.nytimes.com/by/rebecca-robbins I'm posting because I am hoping to hear the perspectives of people living with lung cancer for a news article I'm working on. I'm reporting on prediction markets on platforms like Kalshi and Polymarket that allow people to bet money on whether a drug will win FDA approval. Kalshiannouncedlast week that it is also planning to soon allow people to bet on whether clinical trials will succeed. Here are several prediction markets for lung cancer drug approvals that are already up and active: https://kalshi.com/markets/kxifinatamab/ifinatamab-deruxtecan/kxifinatamab-27 https://kalshi.com/markets/kxivonescimab/ivonescimab/kxivonescimab-27 https://kalshi.com/markets/kxzidesamtinib/zidesamtinib/kxzidesamtinib-27 I'm interested in hearing what people with lung cancer, and in particular those who are currently or have previously enrolled in a clinical trial, think about these prediction markets. If you're interested in being interviewed for this story, you can reach me at 714-478-4224 [email redacted]. From there, we'll set up a phone or video interview. For this article, I'm hoping to speak with people who are comfortable with potentially being quoted in the newspaper using their full name. And beyond this story, I'd also like to hear from you if you have a suggestion for another issue in lung cancer that you think the New York Times should be writing about. Thank you for considering.

nytimes.com logonytimes.com

We Monitor the Web for The New York Times Journo Requests

Never Miss a The New York Times Journo Request

Get instant alerts when The New York Times journalists post new journo requests. Join the community of sources landing media opportunities daily.